沙利文联合时光派发布《2026全球长寿诊所医学干预分级及落地指南》
Frost & Sullivan and TimePie Release “2026 Global Longevity Medicine Clinics: A Guide to Intervention Classification and Implementation”
随着全球人口老龄化加深及健康管理需求升级，长寿医学正从衰老机制研究走向以健康寿命为导向的评估、干预与长期管理。其核心在于结合生物学年龄、器官功能及个体健康状态，识别衰老相关风险，并通过综合评估、个体化干预与动态随访，探索系统化的健康管理路径。不同干预技术在证据基础、临床成熟度及应用边界上存在差异，科学评价与规范落地成为行业发展的关键。
当前，长寿医学产业正逐步形成涵盖上游核心原料与技术、中游检测评估及数字化平台、下游实体诊所与健康管理服务的协作体系。随着政策环境、资本投入及服务供给持续演进，行业发展更加重视技术转化、专业人才与长期服务能力的协同建设。未来，长寿诊所将进一步加强评估、干预与随访的有效衔接，推动行业向规范化、智能化、平台化与生态化发展。
As global population ageing deepens and health management needs evolve, longevity medicine is moving from research into ageing mechanisms toward assessment, intervention, and long-term management focused on healthspan. Central to this approach is the integration of biological age, organ function, and individual health status to identify ageing-related risks and develop systematic health management pathways through comprehensive assessment, personalized intervention, and ongoing follow-up. Differences in the evidence base, clinical maturity, and application boundaries of intervention technologies make scientific evaluation and standardized implementation key priorities for the industry.
The longevity medicine industry is gradually developing a collaborative ecosystem spanning upstream ingredients and technologies, midstream testing, assessment, and digital platforms, and downstream clinics and health management services. As policy frameworks, investment, and service offerings evolve, industry development increasingly depends on coordinated progress in technology translation, professional talent, and long-term service capabilities. Looking ahead, longevity clinics will further integrate assessment, intervention, and follow-up, supporting greater standardization, intelligent services, platform development, and collaboration across the ecosystem.
完整版报告将于近期发布，敬请期待。
